Clinical Trial Update: A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Aplidin (plitidepsin) given as a 3-hour IV infusion in relapsed or refractory multiple myeloma has completed, with results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Aplidin (plitidepsin)

Snippet

Sponsor: PharmaMar | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2009-12-14